

Howard G. Muntz

PROFESSIONAL ADDRESS:

Women's Cancer Care of Seattle
Northwest Hospital & Medical Center
1560 North 115th Street, Suite 101
Seattle, WA 98133

Office: (206) 368-6806

Fax: (206) 368-6808

Confidential Voice Mail: (206) 368-1234, ext. 5873

Email (*not for patients*): howard.muntz@nwseha.org

DATE OF BIRTH:

February 28, 1958
Jackson, Tennessee

EDUCATION

1980 B.A. Vanderbilt University, Nashville, TN
1984 M.D. Harvard Medical School, Boston, MA

POSTDOCTORAL TRAINING:

Internship and Residency:

1984-1988 Obstetrics and Gynecology, Brigham and Women's Hospital and Massachusetts General Hospital, Boston, MA

Fellowships:

1988-1991 Fellow in Gynecologic Oncology, Massachusetts General Hospital
1989-1991 Clinical Oncology Fellow, American Cancer Society

LICENSURE:

1986-1994 Massachusetts License Registration No. 56781
1992-Current Washington State License Registration No. 30427
1994-1996 Alaska State License Registration No. 3380

CERTIFICATION:

1985 National Board of Medical Examiners, Diplomat
1992 American Board of Obstetrics and Gynecology
1994 Certification of Special Qualification in Gynecologic Oncology
2001-Current Annual Board Certification for Maintenance of Certification in Obstetrics and Gynecology, and with Special Qualification in Gynecologic Oncology

PRESENT CLINICAL POSITION:

2008-Present Gynecologic Oncologist, Women's Cancer Care of Seattle, Seattle, WA

CURRENT HOSPITAL APPOINTMENTS AND SERVICE RESPONSIBILITIES:

2008-Present Medical Staff, Northwest Hospital & Medical Center, Seattle, WA
 2008-Present Co-Director, Pelvic Surgery Fellowship, NWH&MC, Seattle, WA
 2008-Present Co-Chair, Gynecologic Cancer Tumor Board, NWH&MC, Seattle, WA
 2008-Present Gynecology Representative, Cancer Committee, NWH&MC, Seattle, WA
 2009-Present Section Head, Obstetrics & Gynecology, NWHMC, Seattle, WA

CURRENT ACADEMIC APPOINTMENT:

2001-present Clinical Associate Professor in Obstetrics & Gynecology, University of Washington School of Medicine

OTHER PROFESSIONAL POSITIONS:

1994-Present Courtesy Staff, Evergreen Hospital, Kirkland, WA
 1994-Present Courtesy Staff, Kennewick General Hospital, Kennewick, WA
 1994-Present Consulting Staff, Group Health Cooperative, Seattle, WA
 1995-Present Courtesy Staff, Kadlec Medical Center, Richland, WA
 1999-Present Courtesy Staff, Swedish Medical Center, Seattle, WA
 2002-Present Courtesy Staff, St. Francis Medical Center, Federal Way, WA
 2008-Present Courtesy Staff, Virginia Mason Medical Center, Seattle, WA

PREVIOUS HOSPITAL APPOINTMENTS:

1988-1989 Clinical Research Fellow, Massachusetts General Hospital, Boston, MA
 1988-1992 Associate Obstetrician-Gynecologist, Brigham & Women's Hospital, Boston, MA
 1989-1991 Assistant in Gynecology, Massachusetts General Hospital, Boston, MA
 1991-1993 Obstetrician-Gynecologist, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Beth Israel Hospital, Boston, MA
 1988-1991 Obstetrician-Gynecologist, Harvard Community Health Plan, Boston, MA
 1992-1993 Consulting Staff, Dana-Farber Cancer Institute, Boston, MA
 1993-2007 Gynecology and Gynecologic Oncology, Department of Surgery, Virginia Mason Medical Center, Seattle, WA

PREVIOUS CLINICAL AND HOSPITAL SERVICE RESPONSIBILITIES:

1989-1991 Attending Physician, Gynecology Service, Massachusetts General Hospital, Boston, MA
 1989-1991 Colposcopy Clinic, Department of Gynecology, Massachusetts General Hospital, Boston, MA
 1989-1991 Gynecologic Oncology Fellow, Cox Ambulatory Oncology Unit, Massachusetts General Hospital, Boston, MA
 1991-1993 Attending Physician, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Beth Israel Hospital, Boston, MA
 1993-2007 Gynecologic Oncologist, Virginia Mason Medical Center, Seattle, WA
 1994-2007 Gynecologic Oncology Consultant, Group Health Cooperative, Seattle, WA
 1999-2003 Gynecology Representative to the Quality Assurance Committee, Virginia Mason Medical Center
 1999-2007 Section Head, Gynecologic Oncology, Virginia Mason Medical Center, Seattle, WA
 2000-2007 Chairman, Gynecologic Cancer Conference and Tumor Board, Virginia Mason Medical Center, Seattle, WA
 2001-2005 Section Head, Gynecology and Gynecologic Oncology, Virginia Mason Medical Center, Seattle, WA

PREVIOUS ACADEMIC APPOINTMENTS:

1984-1989	Clinical Fellow in Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School
1989-1992	Instructor in Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School
1992-1993	Assistant Professor in Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School
1993-2001	Clinical Assistant Professor in Obstetrics & Gynecology, University of Washington School of Medicine

AWARDS AND HONORS:

1976	Harold Sterling Vanderbilt Honor Scholarship
1979	President, Mortar Board Senior Honor Society, Vanderbilt University, Nashville, TN
1980	Phi Beta Kappa
1980	Magna cum laude graduate, Vanderbilt University, Nashville, TN
1980	Phi Eta Sigma Founder's Fund National Scholarship Award
1981	Omicron Delta Kappa National Scholarship Award
1992	Teaching Award, Beth Israel Hospital, Harvard Medical School, Boston, MA
2001-2010	Listed in "Best Doctors in America" (national)
2001-2010	Listed in "Guide to Top Doctors" (national)
2002	Listed in "Seattle Best Doctors," Seattle Magazine, September 2002
2003	Puget Sound Consumer's Checkbook, "Outstanding Physicians"
2005-2010	Listed in "America's Top Doctors for Cancer" (national)
2005	Listed in "Seattle Top Doctors," Seattle Magazine, September 2005
2006-2010	Listed in "Guide to America's Top Obstetricians and Gynecologists" (national)
2006	Listed in "Seattle Top Doctors," Seattle Magazine, September 2006
2006-2007	Cancer Clinical Research Chair Award, Benaroya Research Institute, Seattle, WA
2007	Listed in "Seattle Top Doctors," Seattle Magazine, September 2007
2008-2010	Listed as "Patient's Choice Physician" by MDx Medical (national)
2008-2010	Listed in "Guide to America's Top Oncologists" (national)
2008	Listed in "Washington State's Best Doctors," Washington Travel & Life Magazine
2009	Listed in "Seattle Top Doctors," Seattle Magazine, July 2009.

MEMBERSHIPS IN PROFESSIONAL SOCIETIES:

1989-Present	The American College of Obstetricians and Gynecologists
1992-Present	Society of Gynecologic Oncologists
1993-Present	Washington State Medical Association
1993-Present	King County (Washington) Medical Society
1994-Present	Puget Sound Oncology Consortium Gynecologic Cancer Committee (1998-Present)
1995-Present	Western Association of Gynecologic Oncologists
1995-Present	Gynecologic Oncology Group
1995-Present	Gynecologic Cancer Foundation Membership Committee (1997-2002)
2000-Present	Pacific Ovarian Cancer Research Consortium Physicians Advisory Committee (2000-2004)
2001-Present	Seattle Gynecological Society
2002-Present	Pacific Coast Obstetrical and Gynecological Society

PREVIOUS TEACHING EXPERIENCE:

1978-1980	Laboratory instructor and teaching assistant, Vanderbilt University Chemistry Department
1987-1988	Didactic sessions for Core Clinical Clerkship in Obstetrics and Gynecology, Harvard Medical School
1989-1993	Lecture series in Gynecologic Oncology for medical students and residents, Harvard Medical School
1990	Lecture series in Gynecologic Oncology, Massachusetts General Hospital Institute of Health Professions
1992	Instructor, Harvard Medical School Postgraduate Course on Advanced Colposcopy and Treatment of Intraepithelial Neoplasia of the Lower Female Genital Tract
1994-2005	Director of Ob/Gyn Education at Virginia Mason Medical Center for the University of Washington Department of Obstetrics and Gynecology, including coordinating rotation at VMMC for PGY3 residents
1995-1996	Instructor, Virginia Mason Medical Center Annual Symposium on Cancer
1996	Lecturer, Core Curriculum for Oncology Nurses, Columbia Basin Chapter (WA), Oncology Nursing Society
1999-2007	Director of Virginia Mason Medical Center Pelvic Surgery Fellowship Program

MEDICAL JOURNAL PEER REVIEWER:

American Journal of Obstetrics and Gynecology
Cytopathology
Cancer
European Journal of Gynaecologic Cancer
Gynecological Surgery
Gynecologic Oncology
International Journal of Gynaecologic Cancer
Journal of Clinical Oncology
Obstetrics and Gynecology

MAJOR RESEARCH INTERESTS:

1. Evaluation of treatment regimens for gynecologic malignancies, including clinical trials of novel therapies for ovarian carcinoma.
2. Early diagnosis of ovarian cancer: Is it possible?
3. Evaluation of socioeconomic factors on the delivery of gynecologic oncology care in the United States.
4. Evaluation and treatment of preneoplastic lesions of the lower genital tract.
5. Preservation of fertility in women with cervical adenocarcinoma in-situ.

GRANT SUPPORT:

1. Miscellaneous:
Co-Investigator or collaborator (Women's Cancer Care of Seattle, 2008-current, and Puget Sound Oncology Consortium, 1994-current) for clinical trials in the treatment of gynecologic cancer, including industry-sponsored and GOG cooperative trials.
2. GlaxoSmithKline:
Principal Investigator, "Phase II trial of intraperitoneal topotecan as consolidation therapy in patients with ovarian cancer." (2001–2008)
Investigator-initiated trial at the Benaroya Research Institute at Virginia Mason, supported by a \$150,000 research grant from GlaxoSmithKline.

3. Benaroya Research Institute, Seattle, WA:
Cancer Clinical Research Chair Award, 2006-2007
10% FTE award [\$33,000] for gynecologic oncology research
4. Aventis Pharmaceuticals:
Principal Investigator, "Phase II trial of weekly docetaxel and carboplatin for management of women with epithelial ovarian cancer and similar malignancies." (2004–2008)
Investigator-initiated trial at the Benaroya Research Institute at Virginia Mason, supported by \$33,000 research grant from Aventis Pharmaceuticals.
5. GlaxoSmithKline:
Principal Investigator at the Benaroya Research Institute at Virginia Mason for "Multi-center Phase II study of IV weekly (days 1 and 8 every 21 days) Topotecan in combination with carboplatin (day 1 every 21 days) as second-line therapy in subjects with potentially platinum-sensitive relapsed ovarian cancer." (2005–2008)
6. Antisoma Corporation:
Principal Investigator at the Benaroya Research Institute at Virginia Mason for "Multi-centre randomized survival study of monoclonal antibody radioimmunotherapy (SMART): a multinational study in patients with ovarian carcinoma using the HMFG1 antibody labeled with 90-Yttrium." (1995–2004) [*see Verheijen, et al., J Clin Oncol 2006;24:571-8*]
7. Targeted Genetics Corporation:
Principal Investigator at Benaroya Research Institute at Virginia Mason for "Multi-center phase I dose escalation study of intraperitoneal E1A lipid complex (1:3) with combination chemotherapy in women with epithelial ovarian cancer." (1997–2002)
8. GlaxoSmithKline:
\$10,000 Educational Grant to the Virginia Mason Foundation to support continuing medical education programs for ovarian cancer. (2005)
9. Miscellaneous:
Co-Investigator or collaborator at Benaroya Research Institute, Seattle, WA, (1993-2007) for other clinical trials in the treatment of gynecologic cancer, including industry-sponsored and cooperative trials (CCOP, SWOG, GOG, NSABP).

BIBLIOGRAPHY:

PEER REVIEWED PUBLICATIONS:

1. Muntz HG, Matsuoka N, Jackson RL. Phospholipase activity of bovine milk lipoprotein lipase on phospholipid vesicles: influence of apolipoproteins C-II and C-III. *Biochem Biophys Res Commun* 1979;90:15-21.
2. Jackson RL, Taskinen MR, Matsuoka N, Fitzharris TJ, Harmony JAK, Muntz HG, Neely EK, Cardin AD, Johnson JD. Lipoprotein structure and the mechanism of action of lipoprotein lipase. In: *Atherosclerosis V: Proceedings of the Fifth International Symposium*. New York: Raven Press 1980:180-3.
3. Shirai K, Fitzharris TJ, Shinomiya M, Muntz HG, Harmond JAK, Jackson RL, Quinn, DM. Lipoprotein lipase catalyzed hydrolysis of phosphatidylcholine of guinea pig very low density lipoproteins and discoidal complexes of phospholipid and apolipoprotein; effect of apolipoprotein C-II on the catalytic mechanism. *J Lipid Res* 1983;24:721-30.
4. Muntz HG, Falkenberry S, Fuller AF Jr. Fallopian tube prolapse after hysterectomy. *J Reprod Med* 1988;33:467-9.

5. Muntz HG, Rutgers JL, Tarraza HM, Fuller AF Jr. Carcinosarcomas and mixed mullerian tumors of the fallopian tube. *Gynecol Oncol* 1989;4:109-15.
6. Muntz HG, Tarraza HM, Granai CO, Fuller AF Jr. Primary adenocarcinoma of the fallopian tube. *Eur J Gynaecol Oncol* 1989;10:239-49.
7. Goff BA, Muntz HG. Herpes simplex infection in pregnancy. *Clin Adv Treat Infect* 1990;4:4-5.
8. Goff BA, Muntz HG. Gunshot wounds to the gravid uterus: case report and literature review. *J Reprod Med* 1990;35:436-8.
9. Muntz HG, Goff BA, Fuller FA Jr. Recurrent ovarian granulosa cell tumor: role of combination chemotherapy with report of a long-term response to a cyclophosphamide, doxorubicin, and cisplatin regimen. *Eur J Gynaecol Oncol* 1990;11:263-8.
10. Muntz HG, Tarraza HM, Goff BA, Granai CO, Rice LW, Nikrui N, Fuller AF Jr. Combination chemotherapy in advanced adenocarcinoma of the fallopian tube. *Gynecol Oncol* 1991;40:268-73.
11. Tarraza HM, Muntz HG, Cain DE, Granai CO, Fuller AF Jr. Patterns of recurrence of primary carcinoma of the vagina. *Eur J Gynaecol Oncol* 1991;12:89-92.
12. Toub DB, Goff BA, Muntz HG. Tuberculosis endometritis presenting as postmenopausal bleeding. *J Reprod Med* 1991;36:616-8.
13. Muntz HG, Ferry JA, Flynn D, Fuller AF Jr, Tarraza HM. Stage IE primary malignant lymphoma of the uterine cervix. *Cancer* 1991;68:2023-2032.
14. Muntz HG, Goff BA, Thor AD, Tarraza HM. Posthysterectomy carcinoma of the fallopian tube mimicking a vesicovaginal fistula. *Obstet Gynecol* 1992;79:853-856.
15. Goff BA, Atanasoff P, Brown E, Muntz HG, Bell DA, Rice LW. Endocervical glandular atypia in Papanicolaou smears. *Obstet Gynecol* 1992;79:101-4.
16. Muntz HG, Brown E. Refractory lactic acidosis and hypoglycemia complicating advanced gynecologic malignancy. *Intl J Gynecol Oncol* 1992;2:163-167.
17. Pressley RH, Muntz HG, Falkenberry S, Rice LW. Serum lactic dehydrogenase as a tumor marker in dysgerminoma. *Gynecol Oncol* 1992;44:281-283.
18. Gustafson ML, Lee MM, Scully RE, Moncure AC, Hirakawa T, Goodman AK, Muntz HG, Donahoe PK, MacLaughlin DT, and Fuller AF Jr. Mullerian inhibiting substance as a marker for ovarian sex-cord tumor. *N Engl J Med* 1992;326:466-471.
19. Muntz HG, Bell DA, Lage JM, Goff BA, Feldman S, Rice LW. Adenocarcinoma in-situ of the uterine cervix. *Obstet Gynecol* 1992;80:935-939.
20. Goff BA, Muntz HG, Bell DA, Wertheim I, Rice LW. Human Papillomavirus typing in patients with Papanicolaou smears showing squamous atypia. *Gynecol Oncol* 1993;48:384-388.
21. Tarraza HM, Muntz HG, DeCain M, Jones MA. Cervical metastases in advanced ovarian malignancies. *Eur J Gynaecol Oncol* 1993;14:274-278.
22. Goff BA, Mueller PR, Muntz HG, Rice LW. Small chest-tube drainage followed by bleomycin sclerosis for malignant pleural effusions. *Obstet Gynecol* 1993;81:993-996.

23. Tepler I, Cannistra SA, Frei E, III, Gonin R, Anderson KC, Demetri G, Niloff J, Goodman H, Muntz H, Muto M, Sheets E, Elias AD, Mazanet R, Wheeler C, Ayash L, Schwartz G, McCauley M, Gaynes L, Harvey S, Schnipper LE, Antman KH. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy. *J Clin Oncol* 1993;11:1583-1591.
24. Goff BA, Rice LW, Fleischhacker D, Muntz HG, Falkenberry SS, Nikrui N, Fuller AF Jr. Uterine leiomyosarcoma and endometrial stromal sarcoma: Lymph node metastases and sites of recurrence. *Gynecol Oncol* 1993;50:105-109.
25. Jacoby A, Thor A, Fuller AF Jr, Muntz HG. Leiomyosarcoma of the fallopian tube. *Gynecol Oncol* 1993;51:404-407.
26. Goff BA, Rice LW, Fleischhacker DS, Abujawadeh GM, Muntz HG. Large loop excision of the transformation zone in patients with exocervical squamous intraepithelial lesions. *Eur J Gynaecol Oncol* 1994;15:275-262.
27. Goff BA, Rice LW, Muntz HG, Nikrui N, Fuller AF, Jr. Surgical stage IV endometrial carcinoma. *Gynecol Oncol* 1994;52:237-240.
28. Goff BA, Kato D, Schmidt RA, Ek M, Muntz HG, Cain JM, Tamimi HK, Figge DC, Greer BE. Uterine papillary serous carcinoma: Patterns of metastatic spread. *Gynecol Oncol* 1994;54:264-268.
29. Muntz HG, Jones MA, Goff BA, Rice LW, Nikrui N, Fuller AF, Jr., Tarraza HM. Malignant mixed Mullerian tumors (MMMT) of the ovary: experience with surgical cytoreduction and combination chemotherapy. *Cancer* 1995;76:1209-1213.
30. Swisher EM, Gown AM, Skelly M, Ek M, Tamimi HK, Cain JM, Greer BE, Muntz HG, Goff BA. Expression of epidermal growth factor receptor, p53, her-2/neu, and KI-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcomas. *Gynecol Oncol* 1996;60:81-88.
31. Goff BA, Sainz de le Cuesta R, Muntz HG, Fleischhacker D, Ek M, Rice LW, Nikrui N, Tamimi HK, Cain JM, Greer BE, Fuller AF, Jr. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. *Gynecologic Oncology* 1996;60:412-417.
32. Goff BA, Shy K, Greer BE, Muntz HG, Skelly M, Gown AM. Overexpression and relationships of HER-2/neu, epidermal growth factor receptor, p53, Ki-67, and tumor necrosis factor alpha in epithelial ovarian. *Eur J Gynaecol Oncol* 1996;17:487-492.
33. Goff BA, Muntz HG, Cain JM. Is Adam worth more than Eve? The financial impact of gender bias in the federal reimbursement of gynecologic procedures. *Gynecol Oncol* 1997;64:372-377.
34. Goff BA, Muntz HG, Cain JM. Comparison of 1997 Medicare relative value units for gender-specific procedures: Is Adam still worth more than Eve? *Gynecol Oncol* 1997;66:313-319.
35. Grice J, Marit E, Greer B, Koh WJ, Muntz HG, Cain JM, Tamimi H, Stelzer K, Figge D, Goff BA. Uterine papillary serous carcinoma: Evaluation of long-term survival in surgically staged patients. *Gynecol Oncol* 1998;69:69-73.
36. Goff BA, Muntz HG, Greer BE, Tamimi HK, Gown A. Oncogene expression: Long-term compared with short-term survival in patients with advanced epithelial ovarian cancer. *Obstet Gynecol* 1998;92:88-93.

37. Cohn DE, Peters WA 3rd, Muntz HG, Wu R, Greer BE, Tamimi HK, Drescher CW, Smith MR, Yon JL, Schmidt R, Goff BA. Adenocarcinoma of the uterine cervix metastatic to lymph nodes. *Am J Obstet Gynecol* 1998;178:1131-7.
38. Muntz HG, Goff BA, Madsen BL, Yon JL. Port-site recurrence after laparoscopic surgery for endometrial cancer. *Obstet Gynecol* 1999;93:807-809.
39. Goff BA, Muntz HG, Paley PJ, Tamimi HK, Koh W-J, Greer BE. Impact of surgical staging in women with locally advanced cervical cancer. *Gynecol Oncol* 1999;74:436-442.
40. Muntz HG. "Curbside" consultations in gynecologic oncology: A closer look at a common practice. *Gynecol Oncol* 1999;74:456-459.
41. Goff BA, Mandel LS, Muntz HG, Melancom CH. Ovarian cancer diagnosis: Results of a national ovarian cancer survey. *Cancer* 2000;89:2068-2075.
42. Goff BA, Sallin J, Garcia R, VanBlaricom A, Paley PJ, Muntz HG. Evaluation of p27 in preinvasive and invasive malignancies of the cervix. *Gynecol Oncol* 2003;88:40-44.
43. Muntz HG, Goff BA, McGonigle K, Isacson C. The significance of psammoma bodies in screening cervical cytology smears. *Am J Obstet Gynecol*. 2003;188:1609-1614.
44. Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. *JAMA* 2004;291:2705-2712.
45. Begley JS, Kupferman SP, Kuznetsov DD, Kobashi KC, Govier FE, McGonigle KF, Muntz HG. Incidence and management of abdominal sacrocolpopexy mesh erosions. *Am J Obstet Gynecol* 2005;192:1956-1962.
46. Goff BA, Muntz HG. Ovarian Cancer Screening. *Women's Health in Primary Care* 2005;9:262-268.
47. Govier FE, Kobashi KC, Kozlowski PM, Kuznetsov DD, Begley SJ, McGonigle KF, Muntz HG. High complication rate identified in sacrocolpopexy patients attributed to silicone mesh. *Urology* 2005;65:1099-1103.
48. Muntz HG, McGonigle KD, Malpass TW, Robertson MD, Kamarauskiene D, Weiden P. Phase II study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal cancer. *Cancer Investigation* 2006; 24; 39-41.
49. Goff BA, Matthews BJ, Wynn M, Muntz HG, Lishner DM, Baldwin L-M. Ovarian cancer: Patterns of surgical care across the United States. *Gynecologic Oncology* 2006;103:383-390.
50. Muntz HG, Malpass TW, McGonigle KF, Robertson MD, Weiden PL. Phase II study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and peritoneal carcinoma. *Cancer* 2008; 113:490-6.
51. Rebeles SA, Muntz HG, Wieneke-Broghammer C, Vason ES, McGonigle KF. Robot-assisted total laparoscopic hysterectomy in obese and morbidly obese women. *Journal of Robotic Surgery* 2009;3:141-7.

REVIEWS AND EDITORIALS:

52. Muntz HG. Can cervical adenocarcinoma in situ be safely managed by conization alone? (Editorial) *Gynecol Oncol* 1996;61:301-303.
53. Muntz HG. Understanding the Natural History of Ovarian Cancer, and the Role of Modern Surgical Management. *Virginia Mason Bulletin*, Summer 2004;58:22-27.

54. Muntz HG. Ovarian cancer: Recent advances in combination chemotherapy. *Virginia Mason Bulletin*, Spring 2005;59:25-32.
55. Goff BA, Muntz HG. Ovarian cancer: recognizing symptoms can make a difference. *Contemporary Ob/Gyn*, March 2008; 26-32.

TEXTBOOK CHAPTERS:

1. Muntz HG. Cervical cancer screening and management of the abnormal Papanicolaou smear. In: *Primary Care of Women*. Lemcke DP, Pattison J, Marshall LA, Cowley DS (eds). Appleton & Lange, Norwalk, CT, 1995, pp 467-476.
2. Muntz HG. Fallopian tube. In: *Atlas of Clinical Gynecology*. Goff BA (ed). Current Medicine, Philadelphia, PA, 1998, pp 7.1-7.13.
3. Muntz HG. Cervical cancer screening and management of the abnormal Papanicolaou smear. In: *Current Care of Women: Diagnosis & Treatment*. 2nd Edition. Lemcke DP, Pattison J, Marshall LA, Cowley DS (eds). McGraw-Hill/Appleton & Lange, New York, NY, 2004, pp. 520-531.

SELECTED ABSTRACTS: (Studies presented at national meetings)

1. Muntz HG, Lage J, Bell DA, Goff BA, Feldman S, Rice LW. Adenocarcinoma-in-situ of the uterine cervix. *Proceedings of the Society of Gynecologic Oncologists, 23rd Annual Meeting, San Antonio, TX, March, 1992.*
2. Goff BA, Muntz HG, Cain JM. Is Adam worth more than Eve? The financial impact of gender bias in the federal reimbursement of gynecologic procedures. *Proceedings of the Society of Gynecologic Oncologists, 28th Annual Meeting, March 1997.*
3. Muntz HG. "Curbside" consultations in gynecologic oncology: A closer look at a common practice. *Proceedings of the Society of Gynecologic Oncologists, 30th Annual Meeting, San Francisco, CA, March 1999.*
4. Goff BA, Muntz HG, Paley PJ, Tamimi HK, Koh W-J, Greer BE. Impact of surgical staging in women with locally advanced cervical cancer. *Proceedings of the Society of Gynecologic Oncologists, 30th Annual Meeting, San Francisco, CA, March 1999.*
5. Goff BA, Mandel LS, Muntz HG, Melancon CH. Ovarian cancer diagnosis: Results of a national ovarian cancer survey. *Proceedings of the Society of Gynecologic Oncologists, 31st Annual Meeting, San Diego, CA, February 2000.*
6. Goff BA, Salin J, Rochelle GL, Vanblaricom A, Paley PJ, Muntz HG. Evaluation of p27 expression in preinvasive and invasive malignancies of the cervix. *Proceedings of the Society of Gynecologic Oncologists, 33rd Annual Meeting, Miami, FL, March 16-20, 2002.*
7. Alberts D, Wolf J, Muntz H, Hatch K, Carrier A, Eggert S, Heald A. A phase I, dose-escalation trial of E1A gene transfer with chemotherapy for treatment of advanced ovarian cancer. *Proc Am Soc Clin Oncol* 2002;21:abstract 69.
8. Goff B, Mandel L, Muntz H, Melancon CH. Symptoms of ovarian cancer: how often are they found in women presenting to primary care clinics? *Society of Gynecologic Oncologists, 34th Annual Meeting, New Orleans, LA, January 31–February 4, 2003. Gynecol Oncol* 2003;88:237-238.

9. Goff BA, Mandel LS, Melancon CH, Muntz HG. Ovarian cancer symptoms: a randomized trial. Proceedings of the Society of Gynecologic Oncologists, 35th Annual Meeting, San Diego, CA, February 7-11, 2004.
10. Kuznetsov D, Govier F, Kobashi K, Kozlowski P, Begley S, McGonigle K, Muntz H. A high vaginal erosion rate identified in sacrocolpopexy patients using silicone mesh. Proceedings of the Society for Urodynamics & Female Urology (SUFU), Scottsdale, AZ, Feb 26-29, 2004.
11. Robertson M, Malpass T, McGonigle K, Weiden P, Muntz H. Phase II study of intraperitoneal topotecan as consolidation therapy in ovarian cancer. Proceedings of the American Society of Clinical Oncology 40th Annual Meeting, New Orleans, LA, June 5-8, 2004.
12. Muntz HG, McGonigle KD, Malpass TW, Robertson MD, Kamarauskiene D, Weiden P. Phase II study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal cancer. Society of Gynecologic Oncologists' 36th Annual Meeting, Miami, FL, Feb. 7-11, 2005: abstract 199.
13. Goff B, Larson E, Mathews B, Andrilla H, Lishner D, Baldwin LM, Lackey M, Muntz H. What factors predict comprehensive surgical treatment of ovarian cancer patients? Presented at the 37th Annual Meeting of the Society of Gynecologic Oncologists, March 23, 2006. See *Gynecol Oncol* 2006; 101:S2: abstract 1.
14. Malpass TW, McGonigle KF, Robertson M, Weiden P, Muntz HG. Mature results of a Phase II study of intraperitoneal topotecan as consolidation therapy in ovarian cancer. Proceedings of the American Society of Clinical Oncology 43rd Annual Meeting, Chicago, IL, June 1-5, 2007: Abstract 5570.
15. Schwartz P, Rose P, Monk B, Muntz H, Dharan B, Legenne P, Buller R, Sherman L, Starrs E. IV weekly (days 1 and 8) topotecan in combination with carboplatin (day 1) every 21 days as second-line therapy in subjects with platinum-sensitive relapsed ovarian cancer (OC): Dose selection for a phase II study. Presented at the 15th International Meeting of the European Society of Gynaecological Oncology, October 29, 2007.
16. McGonigle KF, Muntz HG, Vuky J, Paley PJ, Veljovich DS, Gray HJ, Malpass TW. Phase II prospective study of weekly topotecan and bevacizumab in platinum refractory ovarian or primary peritoneal cancer. Proceedings of the American Society of Clinical Oncology 44th Annual Meeting, Chicago, IL, June 1-5, 2008.
17. McGonigle KF, Muntz HG, Vuky J, Paley PJ, Veljovich DS, Gray HJ, Malpass TW. Phase II prospective study of weekly topotecan and bevacizumab in platinum refractory ovarian or primary peritoneal cancer. Presented at the 40th Annual Meeting of the Society of Gynecologic Oncology, San Antonio, TX, February 5-8, 2009.